Literature DB >> 8506293

Systemic immunological effects of cytokine genes injected into skeletal muscle.

E Raz1, A Watanabe, S M Baird, R A Eisenberg, T B Parr, M Lotz, T J Kipps, D A Carson.   

Abstract

Somatic gene therapy is an interesting approach for the delivery of cytokines for prolonged periods. The present experiments show that direct injections into mouse skeletal muscle of cDNA expression vectors encoding interleukin 2 (IL-2), IL-4, or type beta 1 transforming growth factor (TGF-beta 1) induce biological effects characteristic of these cytokines in vivo. Mice injected intramuscularly with a vector encoding IL-2 had enhanced humoral and cellular immune responses to an exogenous antigen, transferrin, that was delivered at a separate site. These IL-2 effects were abolished by coadministration of a vector directing synthesis of TGF-beta 1. The TGF-beta 1 vector by itself depressed the anti-transferrin antibody response and caused an 8-fold increase in plasma TGF-beta 1 activity. The TGF-beta 1 plasmid injection did not cause muscle infiltration with monocytes or neutrophils and there was no evidence for fibrotic changes. Muscle injection with a cDNA encoding IL-4 selectively increased IgG1 levels but did not alter the cellular immune response to transferrin. In lupus-prone mice (MRL/lpr/lpr), injection with IL-2 expression vectors increased and TGF-beta 1 vectors decreased auto-antibodies to chromatin. These results demonstrate that intramuscular injection of cytokine genes, in the absence of infectious viral vectors, can regulate humoral and cellular immune responses in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8506293      PMCID: PMC46544          DOI: 10.1073/pnas.90.10.4523

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

Review 1.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

2.  BSC-1 growth inhibitor/type beta transforming growth factor is a strong inhibitor of thymocyte proliferation.

Authors:  H J Ristow
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

3.  Adenovirus as an expression vector in muscle cells in vivo.

Authors:  B Quantin; L D Perricaudet; S Tajbakhsh; J L Mandel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

4.  Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production.

Authors:  C M Snapper; W E Paul
Journal:  Science       Date:  1987-05-22       Impact factor: 47.728

5.  In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

Authors:  M T Lotze; L W Frana; S O Sharrow; R J Robb; S A Rosenberg
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

6.  Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones.

Authors:  D J Cher; T R Mosmann
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

7.  Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.

Authors:  J H Kehrl; A B Roberts; L M Wakefield; S Jakowlew; M B Sporn; A S Fauci
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

8.  Inhibition of cytokine production by cyclosporin A and transforming growth factor beta.

Authors:  T Espevik; I S Figari; M R Shalaby; G A Lackides; G D Lewis; H M Shepard; M A Palladino
Journal:  J Exp Med       Date:  1987-08-01       Impact factor: 14.307

9.  B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes.

Authors:  M Lotz; F Jirik; P Kabouridis; C Tsoukas; T Hirano; T Kishimoto; D A Carson
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

10.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.

Authors:  J H Kehrl; L M Wakefield; A B Roberts; S Jakowlew; M Alvarez-Mon; R Derynck; M B Sporn; A S Fauci
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

View more
  19 in total

1.  Gene therapy in the treatment of autoimmune diseases.

Authors:  G C Tsokos; G T Nepom
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

2.  Expression of domain III of the envelope protein from GP-78: a Japanese encephalitis virus.

Authors:  Sahil Kulkarni; Sandeepan Mukherjee; Krishna Mohan Padmanabha Das; Kaushiki Prabhudesai; Nupur Deshpande; Sushant Karnik; Abhay S Chowdhary; Usha Padmanabhan
Journal:  Virusdisease       Date:  2017-05-25

3.  Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Kristin Kee; Celsa A Spina; Xiao-Fang Yu; Richard S Kornbluth
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines.

Authors:  J J Kim; L K Nottingham; J I Sin; A Tsai; L Morrison; J Oh; K Dang; Y Hu; K Kazahaya; M Bennett; T Dentchev; D M Wilson; A A Chalian; J D Boyer; M G Agadjanyan; D B Weiner
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

5.  Gene therapy in autoimmune diseases.

Authors:  C H Evans; J D Whalen; C H Evans; S C Ghivizzani; P D Robbins
Journal:  Ann Rheum Dis       Date:  1998-03       Impact factor: 19.103

Review 6.  DNA gene vaccination for HIV.

Authors:  J J Kim; D B Weiner
Journal:  Springer Semin Immunopathol       Date:  1997

7.  The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus.

Authors:  E Eilat; M Dayan; H Zinger; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

Review 8.  Cytokines in rheumatoid arthritis. Potential targets for pharmacological intervention.

Authors:  Z Szekanecz; A E Koch; S L Kunkel; R M Strieter
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

9.  Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc.

Authors:  B R Lawson; G J Prud'homme; Y Chang; H A Gardner; J Kuan; D H Kono; A N Theofilopoulos
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

10.  A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha.

Authors:  H M Horton; D Anderson; P Hernandez; K M Barnhart; J A Norman; S E Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.